{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:09:05Z","timestamp":1788815345286,"version":"build-2803163510"},"reference-count":119,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ijgc.2026.104882","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:17:57Z","timestamp":1785424677000},"page":"104882","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Personalizing endometrial cancer care beyond histology: clinical applications and limits of molecular classification"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4427-0101","authenticated-orcid":false,"given":"Matteo","family":"Marchetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2688-097X","authenticated-orcid":false,"given":"Eleonora","family":"Panizzolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5501-1936","authenticated-orcid":false,"given":"Giuseppe","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Delfrati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2101-0811","authenticated-orcid":false,"given":"Teresa L.","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5458-9417","authenticated-orcid":false,"given":"Tommaso","family":"Meschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1168-2723","authenticated-orcid":false,"given":"Maria Clara","family":"Sant\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1074-0229","authenticated-orcid":false,"given":"Paula","family":"Mateo-Kubach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro T.","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijgc.2026.104882_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104882_bib2","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1016\/S2468-2667(24)00156-7","article-title":"Differences in cancer rates among adults born between 1920 and 1990 in the USA: an analysis of population-based cancer registry data","volume":"9","author":"Sung","year":"2024","journal-title":"Lancet Public Health"},{"issue":"16","key":"10.1016\/j.ijgc.2026.104882_bib3","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-15-2878","article-title":"Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts","volume":"22","author":"Stelloo","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104882_bib4","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1016\/S1470-2045(25)00167-6","article-title":"ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025","volume":"26","author":"Concin","year":"2025","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104882_bib5","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br J Cancer"},{"issue":"10333","key":"10.1016\/j.ijgc.2026.104882_bib6","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","article-title":"Endometrial cancer","volume":"399","author":"Crosbie","year":"2022","journal-title":"Lancet."},{"issue":"7447","key":"10.1016\/j.ijgc.2026.104882_bib7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104882_bib8","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/path.5034","article-title":"The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses","volume":"244","author":"McAlpine","year":"2018","journal-title":"J Pathol"},{"key":"10.1016\/j.ijgc.2026.104882_bib9","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211035959","article-title":"The emerging role of molecular pathology in directing the systemic treatment of endometrial cancer","volume":"13","author":"Jamieson","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104882_bib10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ygyno.2016.07.090","article-title":"Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: earlier prognostic information to guide treatment","volume":"143","author":"Talhouk","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104882_bib11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ygyno.2014.02.012","article-title":"High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma","volume":"133","author":"Stelloo","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104882_bib12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ygyno.2025.10.026","article-title":"Preoperative molecular classification of endometrial cancer: validation through biopsy and matched hysterectomy specimens","volume":"203","author":"Nozaki","year":"2025","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104882_bib13","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2026.37.e67","article-title":"Validation of molecular classification on diagnostic biopsy in endometrial carcinoma: the first step for a tailored approach","volume":"37","author":"Spagnol","year":"2026","journal-title":"J Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104882_bib14","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int J Gynaecol Obstet"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104882_bib15","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1101\/gr.174789.114","article-title":"Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication","volume":"24","author":"Shinbrot","year":"2014","journal-title":"Genome Res"},{"issue":"14","key":"10.1016\/j.ijgc.2026.104882_bib16","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/cncr.33516","article-title":"Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: an individual patient data meta-analysis","volume":"127","author":"McAlpine","year":"2021","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104882_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35731","article-title":"POLE mutations in endometrial carcinoma: clinical and genomic landscape from a large prospective single-center cohort","volume":"131","author":"Nero","year":"2025","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104882_bib18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/ijgc-2023-004864","article-title":"Clinicopathological characteristics of multiple-classifier endometrial cancers: a cohort study and systematic review","volume":"34","author":"De Vitis","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijgc.2026.104882_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2026.104502","article-title":"Redefining endometrial cancer phenotypes in the era of molecular classification and sentinel lymph node mapping: results from a multicenter Italian study","author":"Scarpelli","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"14","key":"10.1016\/j.ijgc.2026.104882_bib20","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1158\/1078-0432.CCR-15-0057","article-title":"POLE proofreading mutations elicit an antitumor immune response in endometrial cancer","volume":"21","author":"van Gool","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"8","key":"10.1016\/j.ijgc.2026.104882_bib21","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1158\/1078-0432.CCR-18-3241","article-title":"Molecular subtype not immune response drives outcomes in endometrial carcinoma","volume":"25","author":"Talhouk","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104882_bib22","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamaoncol.2015.2151","article-title":"Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1","volume":"1","author":"Howitt","year":"2015","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104882_bib23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41698-026-01280-w","article-title":"An interpretable deep learning model for predicting endometrial cancer molecular subtypes from H&E-stained slides","volume":"10","author":"Guo","year":"2026","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.ijgc.2026.104882_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2021.153743","article-title":"ATM immunohistochemistry as a potential marker for the differential diagnosis of no specific molecular profile subtype and POLE-mutation subtype endometrioid carcinoma","volume":"230","author":"Kitazono","year":"2022","journal-title":"Pathol Res Pract"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104882_bib25","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.annonc.2022.05.009","article-title":"Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Oaknin","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104882_bib26","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.3802\/jgo.2024.35.e29","article-title":"Sentinel node mapping in endometrial cancer","volume":"35","author":"Bogani","year":"2024","journal-title":"J Gynecol Oncol"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104882_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102680","article-title":"Sentinel node-positive POLE-mutated endometrial cancer","volume":"35","author":"Bogani","year":"2025","journal-title":"Int J Gynecol Cancer"},{"issue":"27","key":"10.1016\/j.ijgc.2026.104882_bib28","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1200\/JCO.23.00062","article-title":"Molecular classification predicts response to radiotherapy in the randomized PORTEC-1 and PORTEC-2 trials for early-stage endometrioid endometrial cancer","volume":"41","author":"Horeweg","year":"2023","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.ijgc.2026.104882_bib29","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104882_bib30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1470-2045(25)00612-6","article-title":"Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial","volume":"27","author":"van den Heerik","year":"2026","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104882_bib31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/ijgc-2022-004039","article-title":"Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program","volume":"33","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijgc.2026.104882_bib32","unstructured":"Canadian Cancer Trials Group. A Phase II study of tailored adjuvant therapy in POLE-mutated and p53-Wildtype\/NSMP early stage endometrial cancer (RAINBO BLUE & TAPER). ClinicalTrials.gov identifier: NCT05640999. https:\/\/clinicaltrials.gov\/study\/NCT05640999. Accessed May 3, 2026."},{"issue":"5","key":"10.1016\/j.ijgc.2026.104882_bib33","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.3390\/ijms23052653","article-title":"Biomolecular and genetic prognostic factors that can facilitate fertility-sparing treatment (FST) decision making in early stage endometrial cancer (ES-EC): a systematic review","volume":"23","author":"Tanos","year":"2022","journal-title":"Int J Mol Sci."},{"issue":"4","key":"10.1016\/j.ijgc.2026.104882_bib34","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2025.36.e101","article-title":"Analysis of fertility-preserving treatment outcomes in patients with POLE-mutated endometrioid carcinoma","volume":"36","author":"Zhai","year":"2025","journal-title":"J Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104882_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2022-000152","article-title":"Endometrial cancer: molecular classification and future treatments","volume":"1","author":"Corr","year":"2022","journal-title":"BMJ Med"},{"issue":"23","key":"10.1016\/j.ijgc.2026.104882_bib36","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijgc.2026.104882_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1568137","article-title":"Are brain metastases a special issue in POLE-mutated endometrial cancer? a case report series","volume":"15","author":"Ebner","year":"2025","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104882_bib39","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ygyno.2019.10.028","article-title":"Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer","volume":"156","author":"Stasenko","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104882_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102810","article-title":"Key considerations for safe de-escalation of therapy for POLE mutated endometrial cancer","volume":"36","author":"Martin","year":"2026","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijgc.2026.104882_bib41","author":"Artioli"},{"issue":"23","key":"10.1016\/j.ijgc.2026.104882_bib42","doi-asserted-by":"crossref","first-page":"7041","DOI":"10.3390\/jcm13237041","article-title":"The role of immunotherapy in MMR-deficient endometrial carcinoma: state of the art and future perspectives","volume":"13","author":"Marchetti","year":"2024","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104882_bib43","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1264565","article-title":"Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition","volume":"6","author":"Eggink","year":"2016","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104882_bib44","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3390\/jcm14020401","article-title":"PD-1 and PD-L1 expression in endometrial cancer: A systematic review of the literature","volume":"14","author":"De Tommasi","year":"2025","journal-title":"J Clin Med"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104882_bib45","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/jnci\/djab029","article-title":"Prevalence and prognosis of Lynch syndrome and sporadic mismatch repair deficiency in endometrial cancer","volume":"113","author":"Post","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104882_bib46","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1038\/s41436-019-0536-8","article-title":"The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis","volume":"21","author":"Ryan","year":"2019","journal-title":"Genet Med"},{"key":"10.1016\/j.ijgc.2026.104882_bib47","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ygyno.2026.01.233","article-title":"Substratification of mismatch repair deficient endometrial cancers based on mechanism of MMR loss can provide prognostic and predictive refinement","volume":"205","author":"Jamieson","year":"2026","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104882_bib48","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/path.5373","article-title":"Clinicopathological and molecular characterisation of \u2018multiple-classifier\u2019 endometrial carcinomas","volume":"250","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Pathol"},{"key":"10.1016\/j.ijgc.2026.104882_bib49","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ygyno.2023.01.025","article-title":"Molecular subtype stratified outcomes according to adjuvant therapy in endometrial cancer","volume":"170","author":"Jamieson","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104882_bib50","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(25)00379-1","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial","volume":"26","author":"Post","year":"2025","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104882_bib51","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.annonc.2024.08.2242","article-title":"ENGOT-en11\/GOG-3053\/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer","volume":"35","author":"Van Gorp","year":"2024","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104882_bib53","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2025.36.e35","article-title":"A phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer (NIVEC)","volume":"36","author":"Lee","year":"2025","journal-title":"J Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104882_bib54","doi-asserted-by":"crossref","first-page":"7695","DOI":"10.1038\/s41467-024-52098-8","article-title":"Neoadjuvant immune checkpoint blockade in women with mismatch repair deficient endometrial cancer: a phase I study","volume":"15","author":"Eerkens","year":"2024","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104882_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.101644","article-title":"Phase 2b, open-label, single-arm, multicenter pilot study of the efficacy, safety, and tolerability of dostarlimab in women with early-stage mismatch repair-deficient endometrioid endometrial adenocarcinoma","volume":"35","author":"Obermair","year":"2025","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104882_bib56","doi-asserted-by":"crossref","first-page":"370.e1","DOI":"10.1016\/j.ajog.2020.10.003","article-title":"Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer","volume":"224","author":"Chung","year":"2021","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104882_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2024.100024","article-title":"The prognostic impact of molecular classification in endometrial cancer that undergoes fertility-sparing treatment","volume":"35","author":"De Vitis","year":"2025","journal-title":"Int J Gynecol Cancer"},{"issue":"33","key":"10.1016\/j.ijgc.2026.104882_bib58","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.20.01076","article-title":"Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a Phase III trial (NRG Oncology\/GOG0209)","volume":"38","author":"Miller","year":"2020","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ijgc.2026.104882_bib59","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N Engl J Med."},{"issue":"9","key":"10.1016\/j.ijgc.2026.104882_bib60","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(24)00334-6","article-title":"Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Colombo","year":"2024","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104882_bib61","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the Phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104882_bib62","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.annonc.2024.04.007","article-title":"MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy","volume":"35","author":"Pignata","year":"2024","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104882_bib63","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1200\/JCO-24-01326","article-title":"First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: a randomized, open-label, phase III trial-label","volume":"43","author":"Marth","year":"2025","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104882_bib64","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.annonc.2024.05.546","article-title":"Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin\u2013paclitaxel in the randomized ENGOT-EN6\/GOG-3031\/RUBY trial","volume":"35","author":"Powell","year":"2024","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104882_bib65","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/s41591-025-03566-1","article-title":"Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial","volume":"31","author":"Eskander","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104882_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102795","article-title":"First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-year follow-up after final analysis of the ENGOT-en9\/LEAP-001 phase 3 trial","volume":"36","author":"Marth","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2026.104882_bib67","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1200\/JCO.2026.44.16_suppl.5501","article-title":"Long-term survival rates and cure modeling with dostarlimab plus chemotherapy in mismatch repair deficient\/microsatellite instability-high primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO\/GOG-3031\/RUBY trial","volume":"44","author":"Powell","year":"2026","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2026.104882_bib68","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1200\/JCO.2026.44.16_suppl.5502","article-title":"Updated overall survival analysis and examination of subsequent therapy in endometrial cancer participants treated with pembrolizumab plus carboplatin\/paclitaxel as compared to carboplatin\/paclitaxel plus placebo in the NRG-GY018 trial","volume":"44","author":"Eskander","year":"2026","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104882_bib69","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003777","volume":"10","author":"Oaknin","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104882_bib70","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1200\/JCO.21.01874","article-title":"Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study","volume":"40","author":"O\u2019Malley","year":"2022","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ijgc.2026.104882_bib71","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1080\/14796694.2025.2496133","article-title":"DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients","volume":"21","author":"Cherifi","year":"2025","journal-title":"Future Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104882_bib73","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s41379-022-01102-x","article-title":"p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial","volume":"35","author":"Vermij","year":"2022","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104882_bib74","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1136\/ijgc-2020-002256","article-title":"p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification","volume":"31","author":"Jamieson","year":"2021","journal-title":"Int J Gynecol Cancer"},{"issue":"23","key":"10.1016\/j.ijgc.2026.104882_bib75","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1158\/1078-0432.CCR-23-1397","article-title":"Clinical behavior and molecular landscape of stage I p53-abnormal low-grade endometrioid endometrial carcinomas","volume":"29","author":"Jamieson","year":"2023","journal-title":"Clin Cancer Res."},{"issue":"3","key":"10.1016\/j.ijgc.2026.104882_bib76","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1158\/1078-0432.CCR-18-1443","article-title":"Frequent homologous recombination deficiency in high-grade endometrial carcinomas","volume":"25","author":"de Jonge","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"1","key":"10.1016\/j.ijgc.2026.104882_bib77","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3390\/cancers13010044","article-title":"HER2 status in high-risk endometrial cancers (PORTEC-3): relationship with histotype, molecular classification, and clinical outcomes","volume":"13","author":"Vermij","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104882_bib78","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1136\/ijgc-2024-005711","article-title":"Seneca study: staging endometrial cancer based on molecular classification","volume":"34","author":"Chacon","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104882_bib79","doi-asserted-by":"crossref","first-page":"284","DOI":"10.6004\/jnccn.2025.0038","article-title":"NCCN Guidelines\u00ae insights: uterine neoplasms, version 3.2025","volume":"23","author":"Abu-Rustum","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104882_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.103197","article-title":"An open-label randomized multicenter phase 3 study of trastuzumab deruxtecan versus standard of care chemotherapy as adjuvant treatment for patients with HER2-expressing (IHC 3+\/2+) endometrial cancer: DESTINY-Endometrial02","volume":"36","author":"Mathews","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"20","key":"10.1016\/j.ijgc.2026.104882_bib81","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized Phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.ijgc.2026.104882_bib82","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-20-0953","article-title":"Randomized Phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (Stage III\u2013IV) or recurrent uterine serous carcinomas that overexpress Her2\/Neu (NCT01367002): updated overall survival analysis","volume":"26","author":"Fader","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104882_bib83","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 Phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104882_bib84","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ygyno.2022.02.025","article-title":"Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial)","volume":"165","author":"Post","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104882_bib85","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2024.10.022","article-title":"Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR\/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO\/GOG-3031\/RUBY)","volume":"192","author":"Powell","year":"2025","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104882_bib86","doi-asserted-by":"crossref","first-page":"7950","DOI":"10.1038\/s41467-025-62678-x","article-title":"Maintenance olaparib after platinum-based chemotherapy for advanced\/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial","volume":"16","author":"Joly","year":"2025","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104882_bib87","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ygyno.2021.01.025","article-title":"Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced\/recurrent endometrial cancer: an NRG Oncology study","volume":"161","author":"Leslie","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"14","key":"10.1016\/j.ijgc.2026.104882_bib88","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1200\/JCO.20.03167","article-title":"Phase II study of the WEE1 inhibitor adavosertib in recurrent uterine serous carcinoma","volume":"39","author":"Liu","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104882_bib89","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/his.15533","article-title":"Folate receptor alpha (FR\u03b1\/FOLR1) and HER2 immunohistochemical staining in high-grade endometrial carcinoma with aberrant p53 expression","volume":"88","author":"McHenry","year":"2026","journal-title":"Histopathology"},{"key":"10.1016\/j.ijgc.2026.104882_bib90","unstructured":"A phase 2 study of mirvetuximab soravtansine (IMGN853) and pembrolizumab in endometrial cancer (EC). ClinicalTrials.gov. Accessed May 3, 2026. https:\/\/clinicaltrials.gov\/study\/NCT03835819."},{"issue":"9","key":"10.1016\/j.ijgc.2026.104882_bib91","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S1470-2045(19)30395-X","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial","volume":"20","author":"de Boer","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104882_bib92","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104882_bib93","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41416-023-02141-0","article-title":"Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry","volume":"128","author":"Vermij","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijgc.2026.104882_bib94","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ygyno.2025.05.015","article-title":"Prognostic significance of estrogen receptor expression and estrogen signaling in endometrial carcinomas of no specific molecular profile: a comprehensive molecular and pathologic analysis","volume":"198","author":"Lam","year":"2025","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104882_bib95","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejca.2023.03.016","article-title":"Back to the future: The impact of oestrogen receptor profile in the era of molecular endometrial cancer classification","volume":"186","author":"Perrone","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijgc.2026.104882_bib96","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ygyno.2025.07.020","article-title":"The challenge of molecular stratification in No Specific Molecular Profile endometrial cancer","volume":"200","author":"Marchetti","year":"2025","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104882_bib97","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ajog.2025.09.041","article-title":"Prognostic role of immunohistochemical and molecular markers in no specific molecular profile endometrial cancer: a systematic review and meta-analysis","volume":"234","author":"Ferrari","year":"2026","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104882_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2022.100085","article-title":"Grade and estrogen receptor expression identify a subset of no specific molecular profile endometrial carcinomas at a very low risk of disease-specific death","volume":"36","author":"Jamieson","year":"2023","journal-title":"Mod Pathol"},{"issue":"18","key":"10.1016\/j.ijgc.2026.104882_bib99","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.3390\/cancers16183221","article-title":"Low risk and high-risk NSMPs: a prognostic subclassification of no specific molecular profile subtype of endometrial carcinomas","volume":"16","author":"Marchetti","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104882_bib100","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/PGP.0000000000001120","volume":"44","author":"Huvila","year":"2025","journal-title":"Int J Gynecol Pathol"},{"issue":"19","key":"10.1016\/j.ijgc.2026.104882_bib101","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.3390\/cancers15194899","article-title":"Enhanced risk stratification in early-stage endometrial cancer: integrating POLE through droplet digital PCR and L1CAM","volume":"15","author":"Joe","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104882_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2024.100016","article-title":"Performance of molecular classification in predicting oncologic outcomes of fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer","volume":"35","author":"Ferrari","year":"2025","journal-title":"Int J Gynecol Cancer"},{"issue":"16","key":"10.1016\/j.ijgc.2026.104882_bib103","article-title":"Investigating L1CAM and \u03b2-catenin as prognostic indicators in fertility-sparing endometrial cancer treatment","volume":"42","author":"Park","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104882_bib104","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.22.00628","article-title":"A Phase II, two-stage study of letrozole and abemaciclib in estrogen receptor-positive recurrent endometrial cancer","volume":"41","author":"Konstantinopoulos","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2026.104882_bib105","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ygyno.2024.12.003","article-title":"Palbociclib plus letrozole in estrogen receptor-positive advanced\/recurrent endometrial cancer: double-blind placebo-controlled randomized phase II ENGOT-EN3\/PALEO trial","volume":"192","author":"Mirza","year":"2025","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104882_bib106","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000926","article-title":"Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers","volume":"5","author":"Colon-Otero","year":"2020","journal-title":"ESMO Open"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104882_bib107","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1158\/1078-0432.CCR-24-1999","article-title":"A phase II study of fulvestrant plus abemaciclib in hormone receptor\u2013positive advanced or recurrent endometrial cancer","volume":"31","author":"Green","year":"2025","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.ijgc.2026.104882_bib108","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.ygyno.2026.01.053","article-title":"GOG-3039: a phase II trial of abemaciclib plus letrozole in recurrent or persistent endometrioid endometrial carcinoma (NCT04393285)","volume":"208","author":"Huang","year":"2026","journal-title":"Gynecol Oncol"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2026.104882_bib109","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1200\/JCO.2025.43.16_suppl.5513","article-title":"Phase 2 study of letrozole, abemaciclib, and metformin in estrogen receptor (ER)\u2013positive recurrent endometrial cancer (EC)","volume":"43","author":"Konstantinopoulos","year":"2025","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104882_bib110","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1200\/JCO.2014.58.3401","article-title":"Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma","volume":"33","author":"Slomovitz","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104882_bib111","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1158\/1078-0432.CCR-19-0471","article-title":"Everolimus, letrozole, and metformin in women with advanced or recurrent endometrioid endometrial cancer: a multi-center, single arm, phase II study","volume":"26","author":"Soliman","year":"2020","journal-title":"Clin Cancer Res."},{"issue":"3","key":"10.1016\/j.ijgc.2026.104882_bib112","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ygyno.2021.12.031","article-title":"A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: a GOG Foundation study","volume":"164","author":"Slomovitz","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"35","key":"10.1016\/j.ijgc.2026.104882_bib113","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1200\/JCO.22.02906","article-title":"Oral selinexor as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer","volume":"41","author":"Vergote","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104882_bib114","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1136\/ijgc-2024-005412","volume":"34","author":"Vergote","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104882_bib115","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.annonc.2024.02.006","article-title":"Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer","volume":"35","author":"Bogani","year":"2024","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104882_bib116","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104882_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.102860","article-title":"Access to molecular classification in endometrial cancer recommended by ESGO-ESTRO-ESP guidelines: multi-national survey in Eastern Europe","volume":"36","author":"Abacjew-Chmylko","year":"2026","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104882_bib118","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13027-023-00563-2","article-title":"A systematic review of endometrial cancer clinical research in Africa","volume":"19","author":"Anakwenze","year":"2024","journal-title":"Infect Agent Cancer"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104882_bib119","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1136\/ijgc-2023-005017","article-title":"Management of endometrial cancer in Latin America: raising the standard of care and optimizing outcomes","volume":"34","author":"Blanco","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104882_bib120","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ygyno.2021.10.071","article-title":"Cost-effectiveness analysis of tumor molecular classification in high-risk early-stage endometrial cancer","volume":"164","author":"Orellana","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104882_bib121","article-title":"QPOLE: a quick, simple, and cheap alternative for POLE sequencing in endometrial cancer by multiplex genotyping quantitative polymerase chain reaction","volume":"9","author":"Van den Heerik","year":"2023","journal-title":"JCO Glob Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104882_bib122","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35596","article-title":"Challenges in implementation of molecular classification in early stage endometrial cancer-An NRG Oncology cooperative group mixed-methods study","volume":"131","author":"Wilson","year":"2025","journal-title":"Cancer"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26004135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26004135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:46:00Z","timestamp":1788813960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26004135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":119,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1048891X26004135"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104882","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Personalizing endometrial cancer care beyond histology: clinical applications and limits of molecular classification","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104882","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"104882"}}